Predicting effect of pre-exposure prophylaxis on HIV epidemics

The Lancet

Volumn 379, Issue 9835, 2012, Pages 2423-

  Supervie, Virginie ^a,b   Blower, Sally ^c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; CLINICAL EFFECTIVENESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LETTER; MATHEMATICAL MODEL; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; VIRUS TRANSMISSION;

EID: 84862863283     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61057-5     Document Type: Letter

References (5)

1. Kashuba AD, Patterson KB, Dumond JB, Cohen MS. Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet 2012; 379: 2409-11.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-89.
4. Celum C. Drugs for prevention-topical and systemic PrEP. 18th CROI Conference; Feb 17-Mar 2, 2011; Boston, MA, USA.
5. Supervie V, Barrett M, Kahn JS, et al. Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. Sci Rep 2011; 1: 185.